MedTrace Logo

Aripiprazole IM Depot for Chinese Patients With Schizophrenia

NCT03287505 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-12-29

No results posted yet for this study

Summary

This study assess pharmacokinetics and safety of single-administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg in patients with schizophrenia.

Conditions

Interventions

DRUG

Aripiprazole IM Depot

administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.

Sponsors & Collaborators

  • Otsuka Beijing Research Institute

    lead INDUSTRY

Principal Investigators

  • Tao Jiang, Master · Beijing Anding Hospital of Capital Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-23
Primary Completion
2019-11-08
Completion
2019-11-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03287505 on ClinicalTrials.gov